My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Polatuzumab Biosimilar, CD79B Monoclonal Antibody

Polatuzumab Biosimilar, CD79B Monoclonal Antibody

B29, IGB, Ig-beta

Catalog No. Product Name Size List Price (US$) Quantity
C052P Polatuzumab Biosimilar, Human CD79B Monoclonal Antibody 1 mg 175.00
C052P Polatuzumab Biosimilar, Human CD79B Monoclonal Antibody 5 mg 600.00
C052P Polatuzumab Biosimilar, Human CD79B Monoclonal Antibody 20 mg 1200.00
C052P.NA Polatuzumab Biosimilar, N297A Mutant 0.5 mg 375.00
C052P.LA Polatuzumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant 0.5 mg 375.00
Description

C052P: Polatuzumab Biosimilar, CD79B Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-human CD79B monoclonal antibody polatuzumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade polatuzumab biosimilar specifically binds to the human CD79B protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Polatuzumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade polatuzumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is polatuzumab biosimilar research grade? Polatuzumab is a humanized IgG1-kappa monoclonal antibody against the human CD79B protein, which is ubiquitously expressed on the surface of malignant B cells. Polatuzumab vedotin is used to treat diffuse large B-cell lymphoma (DLBCL) after at least two other cancer treatments did not work or have stopped working. It is given in combination with bendamustine (Bendeka, Treanda) and a medicine that contains rituximab (Rituxan). Polatuzumab vedotin works by attaching to CD79b and releasing a toxic substance that kills the cancer cells. Polatuzumab biosimilar uses the same protein sequences as the therapeutic antibody polatuzumab.

Syd Labs provides the following research grade antibody biosimilars used in ADCs:
Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibody
Rovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibody
Trastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibody
Cofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibody
Ifinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibody
Sacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibody
Gemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibody
Polatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibody
Cetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody

Related Links

See our Privacy Policy